Quick Answer
4D Molecular Therapeutics, Inc. reported Operating Income of -$159.55 million for fiscal year 2025.
4D Molecular Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$159.55M | +15.1% |
| 2024 | -$187.84M | -66.4% |
| 2023 | -$112.87M | -2.6% |
| 2022 | -$110.03M | -54.3% |
| 2021 | -$71.33M | -25.9% |
| 2020 | -$56.66M | -11.6% |
| 2019 | -$50.76M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$61.19M | -19.7% | -2.9% |
| June 30, 2025 | -$59.46M | -40.0% | -10.9% |
| March 31, 2025 | -$53.62M | -40.6% | -4.9% |
| September 30, 2024 | -$51.13M | -265.9% | -20.4% |
| June 30, 2024 | -$42.46M | -32.1% | -11.3% |
| March 31, 2024 | -$38.14M | -26.7% | -172.9% |
| September 30, 2023 | -$13.97M | +47.3% | +56.5% |
| June 30, 2023 | -$32.14M | -13.1% | -6.7% |
- 4D Molecular Therapeutics, Inc. showed an increase of +15.1% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, 4D Molecular Therapeutics, Inc.’s operating income has declined by 214.3% (from -$50.76 million to -$159.55 million).
- The most recent figure is from 4D Molecular Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: